{
    "clinical_study": {
        "@rank": "70575", 
        "acronym": "MEI-005", 
        "arm_group": {
            "arm_group_label": "Pracinostat added to  HMA", 
            "arm_group_type": "Experimental", 
            "description": "Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this open label study is to determine whether combining pracinostat (study\n      drug) with Vidaza (azacitidine) or Dacogen (decitabine) will improve clinical responses in\n      Myelodysplastic Syndrome (MDS) patients who have failed an initial single agent\n      hypomethylating agent (HMA), and to provide additional safety and efficacy data."
        }, 
        "brief_title": "Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myelodysplastic Syndrome", 
            "MDS"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Voluntary written informed consent before performance of any study-related procedure\n             not part of normal medical care\n\n          2. Histologically or cytologically documented diagnosis of MDS (any\n             French-American-British classification [FAB] subtype)\n\n          3. Bone marrow blasts >5% and <30% and a peripheral white blood cell (WBC) count of\n             <20,000 /\u00b5L\n\n          4. Bone marrow biopsy, aspirates, and peripheral blood smears within 28 days of first\n             study treatment\n\n          5. Group 1:\n\n             Primary failures:  Progression after their most recent HMA therapy according to IWG\n             criteria after receiving single agent azacitidine and/or single agent decitabine, or\n             has worsening cytopenias (increased transfusion requirement), increased BM blasts,\n             progression to a higher FAB type, or develops additional clinically significant\n             cytogenetic abnormalities; Secondary failures: Relapse after any initial CR, PR, HI,\n             or development of clinically significant cytogenetic abnormalities at any time\n             according to IWG criteria after receiving single agent azacitidine or decitabine\n\n             Group 2:\n\n             Failure to achieve a response (any CR, PR or HI) according to IWG criteria definition\n             of stable disease after the most recent HMA therapy (at least 6 cycles of azacitidine\n             or 4 cycles of decitabine)\n\n          6. Must have demonstrated tolerability to single agent HMA without dose reductions due\n             to non-hematologic toxicity for at least one cycle prior to first study treatment\n\n          7. Able to start combination therapy within 3 months of the last single agent HMA dose\n             with no other therapy for disease under study received during this interval\n\n          8. Not a candidate for hematopoietic stem cell transplant within 4 months of screening\n\n          9. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n\n         10. Adequate organ function as evidenced by:\n\n               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u22642.5 x the\n                  upper limit of normal (ULN)\n\n               -  Total bilirubin \u22641.5 x ULN or total bilirubin of \u22642 mg/dL, whichever is higher\n\n               -  Serum creatinine <2 mg/dL, or creatinine clearance \u226560 mL/min\n\n               -  QTcF interval \u2264470 msec\n\n         11. Female or male patients \u226518 years-of-age\n\n         12. Male patients with female partners of child-bearing potential and female patients of\n             childbearing potential are required to use two forms of acceptable contraception,\n             including one barrier method, during their participation in the study and for 30 days\n             following last dose.  Female patients of childbearing potential must have a negative\n             pregnancy test \u22647 days before first study treatment.\n\n         13. Willingness and ability to understand the nature of this trial and to comply with the\n             trial and follow-up procedures\n\n        Exclusion Criteria:\n\n          1. Received any of the following within the specified time frame after the last single\n             agent HMA dose until the first administration of study medication:\n\n               -  Any therapy for malignancy between the time of single agent HMA and first\n                  on-study treatment, including any investigational agent, chemotherapy,\n                  immunotherapy, biological or hormonal therapy\n\n               -  Hydroxyurea within 48 hours prior to first study treatment\n\n               -  Hematopoietic growth factors: erythropoietin, granulocyte colony stimulating\n                  factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), or\n                  thrombopoietin receptor agonists within 7 days (14 days for Aranesp) prior to\n                  first study treatment\n\n               -  Major surgery within 28 days prior to first study treatment\n\n          2. Patients who are candidates for aggressive chemotherapy (e.g. typical AML induction\n             therapy)\n\n          3. Cardiopulmonary function criteria:\n\n               -  Current unstable arrhythmia requiring treatment\n\n               -  History of symptomatic congestive heart failure (New York Heart Association\n                  [NYHA] Class III or IV)\n\n               -  History of myocardial infarction within 6 months of enrollment\n\n               -  Current unstable angina\n\n          4. Concomitant treatment with agents which have significant activity against histone\n             deacetylase (HDAC) inhibitors is not permitted such as Istodax\n             (romidepsin/depsipetide), or valproic acid\n\n          5. Clinical evidence of central nervous system involvement\n\n          6. Patients with gastrointestinal (GI) tract disease, causing the inability to take oral\n             medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation,\n             prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease\n             (e.g., Crohn's disease, ulcerative colitis)\n\n          7. Active infection with human immunodeficiency virus or chronic hepatitis B or C\n\n          8. Life-threatening illness unrelated to cancer or any serious medical or psychiatric\n             illness that could, in the investigator's opinion, potentially interfere with\n             participation in this study\n\n          9. Presence of a malignant disease within the last 12 months, with the exception of\n             adequately treated in-situ carcinomas, basal or squamous cell carcinoma, or\n             non-melanomatous skin cancer and other concurrent malignancies will be considered on\n             a case by case basis\n\n         10. Inability or unwillingness (including psychological, familial, sociological, or\n             geographical conditions) to comply with trial and/or follow-up procedures as outlined\n             in the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993641", 
            "org_study_id": "MEI-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pracinostat added to  HMA", 
                "description": "Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle.  Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days", 
                "intervention_name": "pracinostat", 
                "intervention_type": "Drug", 
                "other_name": "SB939"
            }, 
            {
                "arm_group_label": "Pracinostat added to  HMA", 
                "description": "All patients will receive the dose and schedule of azacitadine to which they previously failed to respond.  (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)", 
                "intervention_name": "Azacitidine", 
                "intervention_type": "Drug", 
                "other_name": "Vidaza"
            }, 
            {
                "arm_group_label": "Pracinostat added to  HMA", 
                "description": "All patients will receive the dose and schedule of decitabine to which they previously failed to respond.  Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.\nThe 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks.", 
                "intervention_name": "Decitabine", 
                "intervention_type": "Drug", 
                "other_name": "Dacogen"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Azacitidine", 
                "Decitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Myelodysplastic Syndrome", 
            "MDS", 
            "pracinostat", 
            "Hypomethylating Agent", 
            "HMA", 
            "azacitadine", 
            "Vidaza", 
            "decitabine", 
            "dacogen"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "link": {
            "description": "Sponsor website", 
            "url": "http://MEIPharma.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "christie.carter@southerncancercenter.com", 
                    "last_name": "Christie Carter, RN", 
                    "phone": "251-607-5283"
                }, 
                "facility": {
                    "address": {
                        "city": "Mobile", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36608"
                    }, 
                    "name": "Southern Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Brian Heller, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Samer Khaled, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC Norris Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Akil Merchant, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Juli.Murphy@healthonecares.com", 
                    "last_name": "Juli Murphy", 
                    "phone": "720-754-4890"
                }, 
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Colorado Blood Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Michael Maris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Yale School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Steven Gore, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "cokeefe@flcancer.com", 
                    "last_name": "Cara M O'Keefe", 
                    "phone": "239-274-9930"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33916"
                    }, 
                    "name": "Florida Cancer Specialist South"
                }, 
                "investigator": {
                    "last_name": "James Reeves, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cbiermeier@flcancer.com", 
                    "last_name": "Christine Biermeier, CCRP", 
                    "phone": "727-216-1143"
                }, 
                "facility": {
                    "address": {
                        "city": "St Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33705"
                    }, 
                    "name": "Florida Cancer Specialist North"
                }, 
                "investigator": {
                    "last_name": "Joseph Mace, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "s-duffey@nortwestern.edu", 
                    "last_name": "Sara Duffey", 
                    "phone": "312-695-1102"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60601"
                    }, 
                    "name": "Northwestern University"
                }, 
                "investigator": {
                    "last_name": "Shira Dinner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westwood", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66205"
                    }, 
                    "name": "University of Kansas Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Abdulraheem Yacoub, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40536"
                    }, 
                    "name": "University of Kentucky"
                }, 
                "investigator": {
                    "last_name": "John Hayslip, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "slimor@hackensackumc.org", 
                    "last_name": "Sora Limor", 
                    "phone": "551-996-8598"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensak", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "John Theurer Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Stefan Faderl, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hmincey@ohcare.com", 
                    "last_name": "Holly Mincey", 
                    "phone": "513-751-2273", 
                    "phone_ext": "27101"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Oncology Hematology Care"
                }, 
                "investigator": {
                    "last_name": "James Essell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zimmerc@ccf.org", 
                    "last_name": "Cassie Zimmerman", 
                    "phone": "216-636-5646"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic"
                }, 
                "investigator": {
                    "last_name": "Mikkael Sekeres, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "tmcason@tnonc.com", 
                    "last_name": "Tiffany Cason", 
                    "phone": "423-698-1844"
                }, 
                "contact_backup": {
                    "email": "sparker@tnonc.com", 
                    "last_name": "Shelly Parker", 
                    "phone": "423-698-1844"
                }, 
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }, 
                    "name": "Tennessee Oncology-Chattanooga"
                }, 
                "investigator": {
                    "last_name": "Bertrand M Anz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "debra.meyer@scresearch.net", 
                    "last_name": "Debra Meyer, RN", 
                    "phone": "615-524-4029"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology"
                }, 
                "investigator": {
                    "last_name": "Jesus Berdeja, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "april.meche@baylorhealth.edu", 
                    "last_name": "April Meche", 
                    "phone": "214-818-6836"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Baylor University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Moshe Levy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vrbayer@mdanderson.org", 
                    "last_name": "Virginia R Bayer, RN", 
                    "phone": "713-745-1933"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Guillermo Garcia-Manero, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "donna.leissner@usoncology.com", 
                    "last_name": "Donna Leissner, RN", 
                    "phone": "210-595-5626"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Cancer Care Centers of South Texas"
                }, 
                "investigator": {
                    "last_name": "Roger Lyons, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Guillermo Garcia-Manero, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical Improvement Rate defined as the proportion of patients with CR, Marrow CR, PR, and HI.", 
            "measure": "Estimate clinical improvement", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993641"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Response Rate (ORR), defined as the proportion of patients with CR, PR, Marrow CR, HI, SD, transfusion independence, and cytogenetic responses according to the IWG criteria", 
                "measure": "Estimate Overall Response Rate (ORR), including all Complete and Partial Responses, Marrow CR, HI, SD, transfusion independence, and cytogenetic responses", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Complete response (CR) rate, defined as the proportion of patients with a confirmed CR (i.e., confirmed by a CBC at least 4 weeks after CR) according to the IWG criteria", 
                "measure": "Estimate Complete Response (CR) rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Hematologic improvement (HI) rate, defined as the proportion of patients who demonstrate major hematologic improvement as defined by the IWG criteria.  Only patients with pre-treatment abnormal values will be considered for this endpoint at 8 weeks.", 
                "measure": "Estimate Hematologic Improvement (HI) rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Duration of Response (for patients who have achieved CR, PR, or HI), defined as the time from the initial determination of response to the time of disease progression or death on study, whichever occurs first.  For patients who are alive and have not experienced disease progression on study (prior to receiving subsequent/new treatment or stem cell transplant), duration of response will be censored at the day of the last adequate disease assessment.", 
                "measure": "Estimate Duration of Response (DoR)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Progression-Free survival (PFS), defined as the time from first day of study drug administration (Day 1) to either disease progression or death.  Patients who have not progressed or are alive will be censored at the date of last adequate disease assessment", 
                "measure": "Estimate Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "6-12 months"
            }, 
            {
                "description": "Event Free Survival (EFS) defined as the time from first day of study drug administration (Day 1) to failure or death from any cause according to the IWG response criteria. Patients who have not progressed, are alive or died without progression will be censored at the date of last adequate disease assessment", 
                "measure": "Estimate Event Free Survival (EFS)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Overall Survival (OS), defined as the time from the first day of study drug administration (Day 1) to death on study.  Patients who are alive will be censored at the date last known alive.", 
                "measure": "Estimate Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "6-24 months"
            }, 
            {
                "description": "Assess the adverse event (AE) profile of pracinostat combined with either azacitidine or decitabine by clinical review of safety events by grade, relationship and event outcomes.", 
                "measure": "Assess the safety profile of the combination", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Marrow CR rate, defined as bone marrow <5% myeloblasts and decrease by > 50% over pretreatment according to IWG criteria.", 
                "measure": "Estimate Marrow CR rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Transfusion independence, defined as during the treatment period the patient had no RBC transfusions during any 56 consecutive days or more.", 
                "measure": "Assess transfusion independence", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Stable disease rate defined as failure to achieve at least a PR, but no evidence of progression for > 8 weeks according to IWG criteria.", 
                "measure": "Estimate Stable Disease (SD) rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Cytogenetic response rate, defined as complete disappearance of the chromosomal abnormality without appearance of new abnormalities, or partial response of at least 50% reduction of the chromosomal abnormality according to IWG criteria.", 
                "measure": "Estimate Cytogenetic Response rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "MEI Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MEI Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}